Current status of the development of dengue vaccines

Dengue fever is caused by the mosquito-borne dengue virus (DENV), which is endemic in more than 100 countries. Annually, there are approximately 390 million dengue cases, with a small subset manifesting into severe illnesses, such as dengue haemorrhagic fever or dengue shock syndrome. Current treatment options for dengue infections remain supportive management due to the lack of an effective vaccine and clinically approved antiviral. Although the CYD-TDV (Dengvaxia (R)) vaccine with an overall vaccine efficacy of 60 % has been licensed for clinical use since 2015, it poses an elevated risk of severe dengue infections especially in denguena & iuml;ve children below 9 years of age. The newly approved Qdenga vaccine was able to achieve an overall vaccine efficacy of 80 % after 12 months, but it was not able to provide a protective effect against DENV-3 in dengue na & iuml;ve individuals. The Butantan-DV vaccine candidate is still undergoing phase 3 clinical trials for safety and efficacy evaluations in humans. Apart from live-attenuated vaccines, various other vaccine types are also currently being studied in preclinical and clinical studies. This review discusses the current status of dengue vaccine development.